Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Animals
Blood Glucose
/ drug effects
Diabetes Mellitus, Type 2
/ drug therapy
Glucosides
/ adverse effects
Glycated Hemoglobin
/ metabolism
Humans
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2
/ drug effects
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Thiophenes
/ adverse effects
discovery
efficacy
pharmacodynamics
pharmacokinetics
review
safety
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
04
2021
accepted:
25
06
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
31
12
2021
Statut:
epublish
Résumé
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of pharmacotherapeutics for type 2 diabetes management that work by reducing renal reabsorption of glucose. Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes. The primary aim of this review is to summarize the available evidence on the efficacy and safety of ipragliflozin for the management of type 2 diabetes. We also review the discovery, pharmacokinetic, and pharmacodynamic profile of ipragliflozin. To inform our review, we searched MEDLINE, International Pharmaceutical Abstracts, and Embase to identify relevant papers to ipragliflozin use in type 2 diabetes. Clinical trial registries were also searched. Findings from randomized clinical trials demonstrate that compared to placebo, ipragliflozin significantly reduces glucose as measured via Hemoglobin A1c and fasting plasma glucose levels. Ipragliflozin is also associated with weight reduction and an improvement in some, but not all, cardiovascular risk markers. Ipragliflozin has a favourable safety profile with a low risk of hypoglycemia and the rates of common adverse events are not significantly different than placebo. Limited data are available to assess rare and long-term adverse effects. Current evidence shows that ipragliflozin is an effective therapeutic option for the management of glucose control in type 2 diabetes. However, no cardiovascular outcome trials have been conducted to date. Real-world observational studies are still needed to accurately capture any possible rare or long-term adverse events.
Sections du résumé
BACKGROUND
BACKGROUND
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of pharmacotherapeutics for type 2 diabetes management that work by reducing renal reabsorption of glucose. Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes.
OBJECTIVE
OBJECTIVE
The primary aim of this review is to summarize the available evidence on the efficacy and safety of ipragliflozin for the management of type 2 diabetes. We also review the discovery, pharmacokinetic, and pharmacodynamic profile of ipragliflozin.
METHODS
METHODS
To inform our review, we searched MEDLINE, International Pharmaceutical Abstracts, and Embase to identify relevant papers to ipragliflozin use in type 2 diabetes. Clinical trial registries were also searched.
RESULTS
RESULTS
Findings from randomized clinical trials demonstrate that compared to placebo, ipragliflozin significantly reduces glucose as measured via Hemoglobin A1c and fasting plasma glucose levels. Ipragliflozin is also associated with weight reduction and an improvement in some, but not all, cardiovascular risk markers. Ipragliflozin has a favourable safety profile with a low risk of hypoglycemia and the rates of common adverse events are not significantly different than placebo. Limited data are available to assess rare and long-term adverse effects.
CONCLUSION
CONCLUSIONS
Current evidence shows that ipragliflozin is an effective therapeutic option for the management of glucose control in type 2 diabetes. However, no cardiovascular outcome trials have been conducted to date. Real-world observational studies are still needed to accurately capture any possible rare or long-term adverse events.
Identifiants
pubmed: 34285473
doi: 10.2147/DDDT.S281602
pii: 281602
pmc: PMC8286902
doi:
Substances chimiques
Blood Glucose
0
Glucosides
0
Glycated Hemoglobin A
0
SLC5A2 protein, human
0
Sodium-Glucose Transporter 2
0
Sodium-Glucose Transporter 2 Inhibitors
0
Thiophenes
0
ipragliflozin
3N2N8OOR7X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3057-3069Informations de copyright
© 2021 Alkabbani and Gamble.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Am J Epidemiol. 2021 Mar 06;:
pubmed: 33751032
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Cell Metab. 2017 Jul 5;26(1):27-38
pubmed: 28506519
BMJ Open. 2019 Feb 1;9(1):e022577
pubmed: 30813108
N Engl J Med. 2021 Jan 14;384(2):117-128
pubmed: 33200892
N Engl J Med. 2021 Jan 14;384(2):129-139
pubmed: 33200891
Curr Opin Nephrol Hypertens. 2010 Sep;19(5):425-31
pubmed: 20539226
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420
Bioorg Med Chem. 2012 May 15;20(10):3263-79
pubmed: 22507206
Diabetes Technol Ther. 2011 Dec;13(12):1219-27
pubmed: 21854192
Diabetes Res Clin Pract. 2018 Dec;146:240-250
pubmed: 30391333
Diabetes Obes Metab. 2019 Feb;21(2):434-438
pubmed: 30207042
Circulation. 2020 Oct 27;142(17):e265-e286
pubmed: 32981345
Diabetes Obes Metab. 2018 Oct;20(10):2408-2415
pubmed: 29862619
J Diabetes Investig. 2016 May;7(3):366-73
pubmed: 27330723
Am J Physiol Renal Physiol. 2001 Jan;280(1):F10-8
pubmed: 11133510
Clin Drug Investig. 2013 Jul;33(7):489-96
pubmed: 23733389
Diabetes Ther. 2019 Dec;10(6):2201-2217
pubmed: 31606880
Expert Opin Pharmacother. 2021 Feb;22(3):373-387
pubmed: 33012212
Diabetes Obes Metab. 2017 Mar;19(3):348-355
pubmed: 27862830
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639
pubmed: 29540325
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Diabetes Obes Metab. 2015 Feb;17(2):152-60
pubmed: 25347938
Diabetes Care. 2013 May;36(5):1260-5
pubmed: 23359360
Can J Diabetes. 2018 Apr;42 Suppl 1:S1-S5
pubmed: 29650079
Lancet Diabetes Endocrinol. 2020 Jan;8(1):27-35
pubmed: 31862149
Int J Med Sci. 2018 Jun 13;15(9):937-943
pubmed: 30008607
Diabetes Res Clin Pract. 2014 Oct;106(1):50-6
pubmed: 25149596
Exp Clin Endocrinol Diabetes. 2021 Jan;129(1):56-72
pubmed: 29913526
Br J Clin Pharmacol. 2019 Aug;85(8):1808-1819
pubmed: 31026084
Diabetes. 2012 Sep;61(9):2199-204
pubmed: 22923645
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetes Obes Metab. 2015 Mar;17(3):304-8
pubmed: 24919820
Kidney Int. 2009 Jun;75(12):1272-1277
pubmed: 19357717
Trends Pharmacol Sci. 2011 Feb;32(2):63-71
pubmed: 21211857
Diabetol Int. 2016 Sep 9;8(1):76-86
pubmed: 30603310
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Ther Adv Drug Saf. 2021 Jan 26;12:2042098621989134
pubmed: 33552467
Kidney Int Suppl. 2011 Mar;(120):S1-6
pubmed: 21358696
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diab Vasc Dis Res. 2015 Mar;12(2):78-89
pubmed: 25616707
Clin Pharmacokinet. 2014 Nov;53(11):975-88
pubmed: 25316572
Endocr J. 2018 Jul 28;65(7):693-705
pubmed: 29848902
Nutr Diabetes. 2014 Nov 03;4:e143
pubmed: 25365416
BMJ. 2020 Sep 23;370:m3342
pubmed: 32967856
J Diabetes Investig. 2020 Jan;11(1):257-261
pubmed: 31729165
Diabetes Ther. 2014 Dec;5(2):355-66
pubmed: 25424969
Scand J Clin Lab Invest. 1971 Oct;28(2):177-82
pubmed: 5130105
Adv Ther. 2020 Oct;37(10):4356-4369
pubmed: 32845473
Diabetes Care. 2017 Oct;40(10):1364-1372
pubmed: 28751548
BMJ. 2020 Apr 29;369:m1186
pubmed: 32349963
Can J Diabetes. 2020 Oct;44(7):575-591
pubmed: 32972640
Diabetes. 2009 Apr;58(4):773-95
pubmed: 19336687
Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55
pubmed: 23707905
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
J Clin Med. 2020 Jan 18;9(1):
pubmed: 31963648
J Diabetes Investig. 2020 Jul;11(4):1020-1076
pubmed: 33021749
Diabetes Obes Metab. 2019 Nov;21(11):2394-2404
pubmed: 31264755
Sci Rep. 2017 Jun 6;7(1):2824
pubmed: 28588220